Bank of Montreal Can Buys 1,169,044 Shares of Catalent, Inc. (NYSE:CTLT)

Bank of Montreal Can boosted its holdings in Catalent, Inc. (NYSE:CTLT - Free Report) by 181.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,813,167 shares of the company's stock after buying an additional 1,169,044 shares during the period. Bank of Montreal Can owned approximately 1.00% of Catalent worth $109,388,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. O Shaughnessy Asset Management LLC bought a new stake in shares of Catalent in the first quarter worth about $214,000. California State Teachers Retirement System increased its stake in Catalent by 0.4% during the 1st quarter. California State Teachers Retirement System now owns 284,815 shares of the company's stock worth $16,078,000 after purchasing an additional 1,149 shares in the last quarter. National Wealth Management Group LLC acquired a new stake in Catalent during the 1st quarter worth approximately $359,000. Swedbank AB acquired a new position in shares of Catalent in the first quarter valued at approximately $1,659,000. Finally, Redwood Grove Capital LLC increased its position in shares of Catalent by 23.0% during the first quarter. Redwood Grove Capital LLC now owns 308,156 shares of the company's stock worth $17,395,000 after acquiring an additional 57,600 shares in the last quarter.

Insider Activity at Catalent

In other news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,114 shares of company stock worth $305,931. Company insiders own 0.31% of the company's stock.

Analysts Set New Price Targets

Several research firms have issued reports on CTLT. William Blair reissued a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com cut Catalent from a "hold" rating to a "sell" rating in a research note on Friday, November 22nd. Baird R W cut shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird reissued a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. One equities research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $63.40.

Catalent Stock Up 0.3 %

Shares of NYSE CTLT traded up $0.21 during trading hours on Wednesday, hitting $60.96. The company had a trading volume of 56,664 shares, compared to its average volume of 2,030,067. Catalent, Inc. has a 1-year low of $36.74 and a 1-year high of $61.50. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The firm's 50 day moving average is $59.84 and its 200-day moving average is $58.39. The stock has a market capitalization of $11.06 billion, a P/E ratio of -26.88, a price-to-earnings-growth ratio of 2.44 and a beta of 1.16.

Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business's revenue was up 4.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.10) EPS. On average, analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.